Skip to content
Open access

Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment

Sep 2026 · Antimicrobial Agents and Chemotherapy · Vol 70 · 0 citations · 18 references
Medicine

TL;DR

Dose adjustment of ceftibuten-ledaborbactam etzadroxil will be required for patients with reduced renal function, as decreasing renal function was associated with increased plasma exposure and reduced renal clearance.

Abstract

ABSTRACT Ledaborbactam etzadroxil is an orally bioavailable prodrug of ledaborbactam, a broad-spectrum β-lactamase inhibitor being developed in combination with ceftibuten for the treatment of complicated urinary tract infections caused by antibiotic-resistant pathogens. As both agents are primarily eliminated via renal excretion, dose adjustment may be required in patients with impaired renal function. This phase 1 study (NCT05488678) evaluated the pharmacokinetics and safety of ceftibuten and ledaborbactam etzadroxil in participants with normal renal function; mild, moderate, or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. Participants received a single dose of ceftibuten-ledaborbactam etzadroxil (600 mg/600 mg); those with ESRD received doses both before and after hemodialysis. Among 32 enrolled participants, the mean age was 62.2 years, and 81.3% were male. For both ceftibuten and ledaborbactam, decreasing renal function was associated with increased plasma exposure and reduced renal clearance (CLr). In participants with mild, moderate, or severe renal impairment, plasma exposure of ceftibuten increased 1.3-, 2.3-, and 3.7-fold, respectively, and ledaborbactam increased 1.5-, 1.9-, and 4.4-fold, respectively. Ceftibuten CLr decreased from 2.2 L/h in participants with normal function to 0.3 L/h in those with severe impairment, while ledaborbactam CLr decreased from 3.0 to 0.5 L/h. In participants with ESRD, both drugs were moderately removed (23% and 38% for ceftibuten and ledaborbactam, respectively) by hemodialysis. No deaths, serious adverse events, or treatment-related adverse events leading to study drug discontinuation were reported. These results indicate that dose adjustment of ceftibuten-ledaborbactam etzadroxil will be required for patients with reduced renal function. This study is registered with ClinicalTrials.gov as NCT05488678.

Read PDF

Similar papers

Open access Oct 2026

Dose Optimization of Cefazolin for Pediatric Patients with Renal Impairment Using Physiologically Based Pharmacokinetic Modeling (PBPK) in GastroPlus

Background/Objectives: Cefazolin is a first-generation cephalosporin antibiotic widely used for the treatment and prophylaxis of bacterial infections in both adult and pediatric populations. It is predominantly eliminated unchanged by the kidneys. Impaired renal function can reduce its clearance and increase systemic e...

Abdelrahman Abdeen, Y. B. Bin Jardan, Najia Rahim et al. · 0 citations
Clinical trial Oct 2026

Pharmacokinetics and Safety of Deuremidevir Hydrobromide (JT001) in Subjects with Mild and Moderate Renal Impairment: An Open‐Label, Parallel‐Group Phase I Study

Simulations suggested that the approved regimen was suitable for patients with mild renal impairment, whereas a reduced regimen of 300 mg twice daily on Day 1 followed by 200 mg twice daily on Days 2–5 was recommended for patients with moderate renal impairment.

Tong Lu, Xi Tan, Shi-Juan Kuang et al. · 0 citations
Clinical trial Open access Oct 2026

No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies

Abstract Objective Ceftibuten and ledaborbactam etzadroxil are being developed as an oral fixed-dose combination for the treatment of complicated urinary tract infections caused by multidrug-resistant Enterobacterales. This study evaluated their effects on cardiac repolarization using concentration-QTc analyses. Method...

B. Darpo, Hong-Qi Xue, Kamal A. Hamed et al. · 0 citations
Clinical trial Open access Nov 2026

Drug-Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three-Cohort Phase I Study.

To evaluate the effects of rifampicin and itraconazole on the pharmacokinetics (PK) of the Janus kinase 1 (JAK1) inhibitor WXFL10203614 and the effects of steady-state WXFL10203614 on metformin PK and safety. In this single-center, open-label, fixed-sequence, self-controlled Phase I study, 54 healthy participants were...

Jin-Mei Zhou, Meng-Shuang Gao, Dao-Lei Zhou et al. · 0 citations
Open access Oct 2026

Development and validation of a cefepime population pharmacokinetic model to guide treatment for patients with hospital-acquired pneumonia requiring renal replacement

ABSTRACT Cefepime is used in critically ill pneumonia patients, but dosing in renal replacement therapy (RRT) is complicated by altered renal function, extracorporeal removal, and variability in pulmonary epithelial lining fluid (ELF) exposure. We sought to develop an integrated model linking systemic, extracorporeal,...

A. Valadez, Emma Harlan, M. Scheetz et al. · 0 citations
Open access Oct 2026

Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 study.

BACKGROUND AIMS Bemnifosbuvir and ruzasvir are potent pan-genotypic inhibitors of the hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively. This single-arm, Phase 2 study evaluated the efficacy and safety of bemnifosbuvir and ruzasvir in treatment-naïve patients with chronic HCV infection of any genot...

A. Jucov, B. Conway, J. Feld et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.